SCHEMBL2664534

SCHEMBL2664534

O=C(Nc1ncc(C(=O)O)s1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.68
CCNE1 P24864 1/20 0.62
CDK2 P24941 1/20 0.62
CDK5 Q00535 1/20 0.62
SCD O00767 2/20 0.61
LCK P06239 1/20 0.60
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
MAPK13 O15264 2/20 0.54
MAPK12 P53778 2/20 0.54
MAPK11 Q15759 2/20 0.54
MAPK14 Q16539 2/20 0.54
ALDH1A1 P00352 1/20 0.53
TSHR P16473 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580537 0.88 KDR (0.61) KDRCCNE1CDK2CDK5SCD
SCHEMBL27727733 0.86 SMN1; SMN2 (0.55) KDRCCNE1CDK2CDK5SCD
SCHEMBL2370632 0.84 CYP1A2 (0.58) KDRCCNE1CDK2CDK5SCD
SCHEMBL31706355 0.84 SCD (0.55) KDRCCNE1CDK2CDK5SCD
SCHEMBL3584763 0.82 KDR (0.57) KDRCCNE1CDK2CDK5SCD
SCHEMBL31705888 0.81 LMNA (0.56) SCDNPC1RAB9AALDH1A1TSHR
SCHEMBL4716373 0.81 MAPK14 (0.59) LCKNPC1RAB9ACYP1A2CYP2C9
SCHEMBL1270133 0.81 SMN1; SMN2 (0.75) KDRCCNE1CDK2CDK5SCD
SCHEMBL836669 0.81 KDR (0.68) KDRCCNE1CDK2CDK5SCD
SCHEMBL10252594 0.81 KDR (1.00) KDRCCNE1CDK2CDK5SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025215188-A1 THERAPEUTIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PKMYT1 MY-T BIO LIMITED (GB) 2025-10-16 WO disclosed
CN-101492416-B compounds effecting glucokinase ASTRAZENECA AB (SE) 2012-02-22 CN disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
CN-101704797-A compounds effecting glucokinase ASTRAZANECA AB 2010-05-12 CN disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
CN-101492416-A Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-07-29 CN disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 KDR 1821/4885CCNE1 816/4885CDK2 142/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 KDR 1821/4885CCNE1 816/4885CDK2 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.